Amgen (AMGN) SVP Rachna Khosla exercises 1,252 options and sells 3,252 shares
Rhea-AI Filing Summary
Amgen Inc. senior vice president of business development Rachna Khosla reported a set of option-related and open-market transactions. On 2026-08-13 she exercised 1,252 options at $162.60 per share to acquire 1,252 common shares, then sold those 1,252 shares at an average price of $416.4256, including shares sold to cover the option exercise price and required withholding taxes. She also sold 2,000 common shares on 2026-08-11 at an average price of $412.567 per share.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
4 txns
Insider
Khosla Rachna
Role
SVP, Business Development
Sold
3,252 shs ($1.35M)
Approx. gross sale proceeds
$1.35M
Approx. exercise cost
$204K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Nqso (Right to Buy) | 1,252 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,252 | $162.60 | $204K |
| Sale | Common Stock F1, F2 | 1,252 | $416.4256 | $521K |
| Sale | Common Stock | 2,000 | $412.567 | $825K |
Holdings After Transaction:
Nqso (Right to Buy) — 0 shares (Direct);
Common Stock — 6,404 shares (Direct)
Footnotes (2)
- F1. Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.
- F2. These shares include 69 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
Key Figures
Options exercised: 1,252 shares
Option exercise price: $162.60 per share
Sale on 2026-08-13: 1,252 shares at $416.4256
+3 more
6 metrics
Options exercised
1,252 shares
Non-qualified stock options exercised on 2026-08-13
Option exercise price
$162.60 per share
Exercise price for 1,252 options exercised on 2026-08-13
Sale on 2026-08-13
1,252 shares at $416.4256
Common stock sale including shares to cover exercise price and taxes
Sale on 2026-08-11
2,000 shares at $412.567
Open-market or private transaction in common stock
Total shares sold
3,252 shares
Aggregate common shares sold across reported transactions
Option grant term
2019-05-01 to 2027-05-01
Exercise and expiration dates for the exercised options
Key Terms
Dividend Equivalents (DEs), Restricted Stock Units, withholding taxes, Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan, +1 more
5 terms
Dividend Equivalents (DEs) financial
"These shares include 69 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc."
Restricted Stock Units financial
"DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
withholding taxes financial
"Includes shares sold to cover the option exercise price and required withholding taxes"
Withholding taxes are amounts a payer or government takes out of payments — such as wages, interest, or dividends — before the recipient gets the money, functioning like a cashier keeping part of a bill to pay taxes on your behalf. For investors this matters because it reduces the cash they actually receive, affects net returns and yield calculations, and may require additional paperwork or treaty claims to recover or offset the withheld amount against final tax bills.
Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan financial
"granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan"
dividend reinvestment plan financial
"subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting"
A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.
FAQ
What insider transactions did Amgen (AMGN) executive Rachna Khosla report?
Rachna Khosla reported exercising 1,252 options and selling a total of 3,252 common shares. The activity included one option exercise and two sales on 2026-08-11 and 2026-08-13 at prices above $400 per share.
At what price did Amgen (AMGN) SVP Rachna Khosla exercise her stock options?
She exercised 1,252 stock options at $162.60 per share. These options, originally granted as non-qualified stock options, had an exercise date of 2019-05-01 and an expiration date of 2027-05-01, and converted into common stock upon exercise.
What are the Dividend Equivalents mentioned in the Amgen (AMGN) Form 4 footnotes?
The filing notes that certain reported shares include 69 Dividend Equivalents (DEs), credited to unvested Restricted Stock Units. DEs are paid out in Amgen common stock on a one-to-one basis under a qualifying dividend reinvestment plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
